Cystic Fibrosis (CF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
NEW YORK, Sept. 13, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Cystic Fibrosis (CF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
http://www.reportlinker.com/p0611552/Cystic-Fibrosis-CF-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
Cystic Fibrosis (CF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, "Cystic Fibrosis (CF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Cystic Fibrosis Therapeutics market. The report identifies the key trends shaping and driving the global Cystic Fibrosis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Cystic Fibrosis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Cystic Fibrosis Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Cystic Fibrosis Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Cystic Fibrosis Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Cystic Fibrosis Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Cystic Fibrosis Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Cystic Fibrosis Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Cystic Fibrosis Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Cystic Fibrosis Therapeutics market landscape? – Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 CF Therapeutics: Introduction 7
2.1 Overview 7
2.2 Etiology and Pathophysiology 8
2.3 Epidemiology 11
2.4 Symptoms 12
2.5 Diagnosis 12
2.6 Treatment and Management Pattern 13
2.7 GlobalData Report Guidance 15
3 CF Therapeutics: Market Characterization 16
3.1 CF Therapeutics Market Size (2005-2010) – Global 16
3.2 CF Therapeutics Market Forecast (2010-2018) – Global 17
3.3 CF Therapeutics Market Size (2005-2010): The US 18
3.4 CF Therapeutics Market Forecast (2010-2018): The US 19
3.5 CF Therapeutics Market (2005-2010): France 20
3.6 CF Therapeutics Market Forecast (2010-2018): France 21
3.7 CF Therapeutics Market (2005-2010): Germany 22
3.8 CF Therapeutics Market Forecast (2010-2018): Germany 23
3.9 CF Therapeutics Market (2005-2010): Italy 24
3.10 CF Therapeutics Market Forecast (2010-2018): Italy 25
3.11 CF Therapeutics Market (2005-2010): Spain 26
3.12 CF Therapeutics Market Forecast (2010-2018): Spain 27
3.13 CF Therapeutics Market (2005-2010): The UK 28
3.14 CF Therapeutics Market Forecast (2010-2018): The UK 29
3.15 CF Therapeutics Market (2005-2010): Japan 30
3.16 CF Therapeutics Market Forecast (2010-2018): Japan 31
3.17 Drivers and Barriers for the CF Therapeutics Market 32
3.17.1 Drivers for the CF Therapeutics Market 32
3.17.2 Barriers for the CF Therapeutics Market 33
3.18 Opportunity and Unmet Need Analysis 33
3.19 Key Takeaway 34
4 CF Therapeutics: Competitive Assessment 35
4.1 Overview 35
4.2 Strategic Competitor Assessment 35
4.3 Product Profile for the Major Marketed Products in the CF Therapeutics Market 36
4.3.1 TOBI (tobramycin Inhalation Solution) 36
4.3.2 Pulmozyme (dornase alfa) 37
4.3.3 Creon (pancrelipase capsules) 38
4.3.4 Cayston (aztreonam for inhalation solution) 39
4.3.5 Colistimethate sodium (Colistin, Colomycin Injection, Promixin, Coly-Mycin M) 40
4.4 Key Takeaway 42
5 CF Therapeutics: Pipeline Assessment 43
5.1 Overview 43
5.2 Strategic Pipeline Assessment 43
5.3 CF Therapeutics Pipeline – Pipeline by Phases of Development 43
5.3.1 CF Therapeutics – Phase III Pipeline 44
5.3.2 CF Therapeutics – Phase II Pipeline 44
5.3.3 CF Therapeutics – Phase I Pipeline 45
5.3.4 CF Therapeutics – Preclinical Pipeline 45
5.3.5 CF Therapeutics – Discovery Pipeline 46
5.4 CF Therapeutics Market – Clinical Pipeline by Mechanism of Action 47
5.5 Technology Trends Analytical Framework 48
5.6 CF Therapeutics – Promising Drugs Under Clinical Development 49
5.7 Molecule Profile for Promising Drugs Under Clinical Development 50
5.7.1 VX-770 50
5.7.2 Ataluren (PTC-124) 51
5.7.3 Bronchitol 52
5.7.4 Arikace (liposomal amikacin for inhalation) 52
5.7.5 MP-376 (levofloxacin solution for inhalation) 53
5.7.6 Spiriva (tiotropium bromide) 53
5.7.7 Bramitob Nebuliser Solution 53
5.7.8 PARI Tobramycin 100 (inhalation) 54
5.8 Key Takeaway 54
6 CF Therapeutics: Clinical Trials Mapping 55
6.1 Clinical Trials by Region/Country (the US, EU5, and Japan) 55
6.2 Clinical Trials by Phase 56
6.3 Clinical Trials by Trial Status 57
6.4 Clinical Trials by Overall Sponsors 58
6.5 Prominent Sponsors 59
6.6 Key Companies Participating in Therapeutics Clinical Trials 60
7 CF Therapeutics: Stategic Assessment 61
7.1 Key Events Impacting the Future Market 61
7.2 CF Therapeutics: Implications for Future Market Competition 62
8 CF Therapeutics: Future Players 64
8.1 Introduction 64
8.2 Company Profiles 65
8.2.1 Vertex Pharmaceuticals Inc. 65
8.2.2 PTC Therapeutics, Inc: 66
8.2.3 Mpex Pharmaceuticals, Inc. 66
8.2.4 Insmed Incorporated 67
8.2.5 Aradigm Corporation 68
8.2.6 GlaxoSmithKline plc 69
8.2.7 Actelion Ltd. 70
8.2.8 Parion Sciences, Inc 71
8.2.9 Chiesi Farmaceutici SpA. 72
9 CF Therapeutics: Licensing and Partnership Deals 74
10 CF Therapeutics: Appendix 77
10.1 Market Definitions 77
10.2 Abbreviations 77
10.3 Methodology 78
10.3.1 Coverage 78
10.3.2 Secondary Research 78
10.3.3 Forecasting 79
10.3.4 Primary Research 82
10.3.5 Expert Panel Validation 82
10.4 Contact Us 82
10.5 Disclaimer 82
10.6 Bibliography 83
1.1 List of Tables
Table 1: Symptoms Associated with CF 12
Table 2: CF Therapeutics Market, Global, Revenue ($m), 2005-2010 16
Table 3: CF Therapeutics Market, Global, Forecast ($m), 2010-2018 17
Table 4: CF Therapeutics Market, the US, Revenue ($m), 2005-2010 18
Table 5: CF Therapeutics Market, the US, Forecast ($m), 2010-2018 19
Table 6: CF Therapeutics Market, France, Revenue ($m), 2005-2010 20
Table 7: CF Therapeutics Market, France, Forecast ($m), 2010-2018 21
Table 8: CF Therapeutics Market, Germany, Revenue ($m), 2005-2010 22
Table 9: CF Therapeutics Market, Germany, Forecast ($m), 2010-2018 23
Table 10: CF Therapeutics Market, Italy, Revenue ($m), 2005-2010 24
Table 11: CF Therapeutics Market, Italy, Forecast ($m), 2010-2018 25
Table 12: CF Therapeutics Market, Spain, Revenue ($m), 2005-2010 26
Table 13: CF Therapeutics Market, Spain, Forecast ($m), 2010-2018 27
Table 14: CF Therapeutics Market, the UK, Revenue ($m), 2005-2010 28
Table 15: CF Therapeutics Market, the UK, Forecast ($m), 2010-2018 29
Table 16: CF Therapeutics Market, Japan, Revenue ($m), 2005-2010 30
Table 17: CF Therapeutics Market, Japan, Forecast ($m), 2010-2018 31
Table 18: CF Therapeutics – Strategic Competitor Assessment, 2011 35
Table 19: Major Marketed Products Analysis in the CF Therapeutics Market, 2011 41
Table 20: CF Therapeutics Market – Phase III Pipeline, 2011 44
Table 21: CF Therapeutics Market – Phase II Pipeline, 2011 44
Table 22: CF Therapeutics Market – Phase I Clinical Pipeline, 2011 45
Table 23: CF Therapeutics Market – Preclinical Clinical Pipeline, 2011 45
Table 24: CF Therapeutics Market – Discovery Clinical Pipeline, 2011 46
Table 25: Cystic Fibrosis – Most Promising Drugs Under Clinical Development, 2010 49
Table 26: CF Therapeutics Market, Clinical Trials by Region, 2011 55
Table 27: CF Therapeutics Market, Global, Clinical Trials by Phase of Development, 2011 56
Table 28: CF Therapeutics Market, Global, Clinical Trials by Trial Status, 2011 57
Table 29: CF Therapeutics Market, Global, Clinical Trials by Overall Sponsors, 2011 58
Table 30: CF Therapeutics Market, Global, Clinical Trials by Prominent Sponsors, 2011 59
Table 31: CF Therapeutics Market, Global, Clinical Trials by Lead Sponsors, 2011 60
Table 32: Pipeline Molecules 2011 66
Table 33: Pipeline Products 2011 66
Table 34: Pipeline Product 2011 67
Table 35: Pipeline Product 2011 68
Table 36: Pipeline Product 2011 69
Table 37: Product pipeline 2011 70
Table 38: Pipeline Products 2011 71
Table 39: Pipeline Products 2011 72
Table 40: Pipeline Products 2011 73
Table 41: Licensing and Partnership Deals 74
1.2 List of Figures
Figure 1: Inheritance of CF in Next Generation 7
Figure 2: Comparison Between Classic and Non-Classic Cystic Fibrosis 8
Figure 3: CFTR Channel Mutation and Regulation of the Chloride Channel 9
Figure 4: Pathophysiology of CF in the Lungs 10
Figure 5: CF Manifestation in the Pancreas 11
Figure 6: Diagnosis Algorithm for CF 13
Figure 7: Treatment Algorithm for CF 14
Figure 8: CF Therapeutics Market, Global, Revenue ($m), 2005-2010 16
Figure 9: CF Therapeutics Market, Global, Forecast ($m), 2010-2018 17
Figure 10: CF Therapeutics Market, the US, Revenue ($m), 2005-2010 18
Figure 11: CF Therapeutics Market, the US, Forecast ($m), 2010-2018 19
Figure 12: CF Therapeutics Market, France, Revenue ($m), 2005-2010 20
Figure 13: CF Therapeutics Market, France, Forecast ($m), 2010-2018 21
Figure 14: CF Therapeutics Market, Germany, Revenue ($m), 2005-2010 22
Figure 15: CF Therapeutics Market, Germany, Forecast ($m), 2010-2018 23
Figure 16: CF Therapeutics Market, Italy, Revenue ($m), 2005-2010 24
Figure 17: CF Therapeutics Market, Italy, Forecast ($m), 2010-2018 25
Figure 18: CF Therapeutics Market, Spain, Revenue ($m), 2005-2010 26
Figure 19: CF Therapeutics Market, Spain, Forecast ($m), 2010-2018 27
Figure 20: CF Therapeutics Market, the UK, Revenue ($m), 2005-2010 28
Figure 21: CF Therapeutics Market, the UK, Forecast ($m), 2010-2018 29
Figure 22: CF Therapeutics Market, Japan, Revenue ($m), 2005-2010 30
Figure 23: CF Therapeutics Market, Japan, Forecast ($m), 2010-2018 31
Figure 24: Opportunity and Unmet Need in the CF Therapeutics Market, 2011 34
Figure 25: CF Therapeutics Pipeline by Phase of Clinical Development, 2011 43
Figure 26: CF Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2011 47
Figure 27: Technology Trends Analytic Framework for the CF Therapeutics Pipeline, 2011 48
Figure 28: Technology Trends Analytic Framework for the CF Therapeutics Pipeline, 2011 49
Figure 29: CF Therapeutics Market – Clinical Trials by Region, 2011 55
Figure 30: CF Therapeutics Market, Global, Clinical Trials by Phase of Development, 2011 56
Figure 31: CF Therapeutics Market, Global, Clinical Trials by Trial Status, 2011 57
Figure 32: CF Therapeutics Market, Global, Clinical Trials by Overall Sponsors, 2011 58
Figure 33: CF Therapeutics Market, Global, Clinical Trials by Prominent Sponsors, 2011 59
Figure 34: CF Therapeutics Market, Global, Clinical Trials by Top Companies, 2011 60
Figure 35: Drivers and Barriers of the CF Therapeutics Market 61
Figure 36: Implications for Future Market Competition in the CF Therapeutics Market, 2011 62
Figure 37: CF Therapeutics Market – Clinical Pipeline by Company, 2011 64
Figure 38: GlobalData Market Forecasting Model 81
Companies mentioned
Vertex Pharmaceuticals Inc.
PTC Therapeutics, Inc:
Mpex Pharmaceuticals, Inc.
Insmed Incorporated
Aradigm Corporation
GlaxoSmithKline plc
Actelion Ltd.
Parion Sciences, Inc
Chiesi Farmaceutici SpA.
To order this report:
Drug and Medication Industry: Cystic Fibrosis (CF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Drug and Medication Business News
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article